Cognitive and Memory Enhancer Drugs: Global Market Analysis (2017-2018) with Forecasts to 2023 - Focus on Product and Application - ResearchAndMarkets.com

DUBLIN--()--The "Cognitive and Memory Enhancer Drugs Market by Product and Application - Global Opportunity Analysis and Industry Forecast, 2017-2023" report has been added to ResearchAndMarkets.com's offering.

According to the report, the global cognitive and memory enhancer drugs market was valued at $3,680 million in 2016, and is projected to reach $6,598 million by 2023, growing at a CAGR of 8.6% from 2017 to 2023. Namenda held more than one-fourth share of the total market in 2016.

The major factors that contribute to the market growth include growth in geriatric population prone to neurological disorders such as Alzheimer's. Moreover, rise in adoption of cognitive drugs owing to its benefits such as improved physical and mental performance boosts the market growth. However, the ethical issues related with the use of such drugs restrain the growth of this market.

Namenda generated the maximum revenue in the global cognitive and memory enhancer drugs market in 2016, and is expected to dominate the market till 2023. Exelon segment is expected to register the highest CAGR of 10.9% during the forecast period, owing to increase in awareness among people towards improved physical performance.

Disease treatment application segment is expected to dominate the market in the future, owing to increase in the number of patients suffering from neurological diseases such as Alzheimer's. On the other hand, academic performance segment is estimated to exhibit a CAGR of 10.2% during the forecast period

Key Findings

  • Razadyne contributed for more than one-sixth share of the global cognitive and memory enhancer drugs market in 2016.
  • Provigil is projected to grow at a significant CAGR of 10.4% during the analysis period.
  • Athletic performance is expected to grow at a significant CAGR of 9.8% from 2017 to 2023.
  • Germany and France were the major shareholders in 2016, together accounting for more than one-third share of the European cognitive and memory enhancer drugs market.
  • Japan was the major shareholder in 2016, accounting for more than one-third share of the Asia-Pacific market.

Key Topics Covered

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview

Chapter 4: Cognitive and Memory Enhancer Drugs Market, by Product

Chapter 5: Cognitive and Memory Enhancer Drugs Market by Application

Chapter 6: Cognitive and Memory Enhancer Drugs Market by Region

Chapter 7: Company Profiles

  • Allergan Plc.
  • AlternaScript LLC
  • Ceretropic
  • Eisai Co. Ltd.
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer Inc.
  • Shire Plc.
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)

For more information about this report visit https://www.researchandmarkets.com/research/df9hfw/cognitive_and?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs